Noticias Celltex
Houston regenerative medicine leaders host delegation from Mexico
A blue ribbon delegation, composed of representatives from the offices of the Secretary of Health of Mexico, the Commission for the Protection against Sanitary Risk (COFEPRIS) — the equivalent of the U.S. FDA in Mexico — and The National Institute of Public Health Mexico (INSP) — the equivalent of the U.S. NIH in Mexico — recently spent two days in Houston and College Station. The purpose of their trip was to meet with leading researchers and doctors to explore the latest regenerative medicine advancements, specifically those using autologous mesenchymal stem cells. The visit was initiated by David Eller, CEO of Houston-based biotechnology company Celltex Therapeutics Corporation.
“We were honored to host these esteemed experts, who came to Houston to learn about our company,” says Eller. “We are excited about their expressed interest in establishing shared relationships with Celltex and other leaders in their respective fields who are using autologous stem cells to initiate technological breakthroughs in the accelerating field of regenerative medicine.”
PHOTO: The delegation visited Houston-based biotechnology company, Celltex. From left to right: Luis Ortiz Blas (INR); Dr. Ana Luisa Sesman Bernal (COFEPRIS); Julio Sánchez y Tépoz (COFEPRIS); José Clemente Ibarra Ponce de León (INR); Dr. Guillermo M. Ruiz-Palacios (INSP); David Eller (Celltex); Dr. Stan Jones (Celltex); Alejandro Sanders (INR); Erik Eller (Celltex)
The delegation met with Dr. Darwin J. Prockop, Director of the Institute for Regenerative Medicine, Texas A&M College of Medicine – Texas A&M University; Dr. Philip A. Salem, a physician, researcher, educator and international statesman in cancer medicine, and President of Salem Oncology Center in Houston; Dr. Mark Adickes, Chief of the Division of Sports Medicine at Baylor College of Medicine; Dr. Stanley Jones, Celltex Chief Medical Officer and Dr. Jane Young, Celltex Chief Scientific Officer, as well as other researchers from Houston’s regenerative medicine community.
Noticias más recientes
Desarrollo de terapias COVID-19 a partir de tejidos de parto y sangre del cordón
Celltex Therapeutics Corporation se mencionó en la publicación Stem Cell Journals como uno de los cinco ensayos de terapia con células madre más grandes que utilizan MSC para combatir el COVID en un artículo titulado “Desarrollo de terapias COVID-19 a partir de tejidos de parto y sangre del cordón umbilical”.
Leer másCompañía de Houston obtiene luz verde para estudiar sus propias células madre para prevenir COVID-19
Noticias prometedoras de Houston de una empresa que obtuvo la autorización de la FDA para intentar usar las propias células madre de una persona para prevenir el COVID-19. Celltex Therapeutics Corporation también espera que las células madre ayuden a tratar algunos de los casos más graves.
Leer más